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Abstract
Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality.
However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an
international consensus group, including the International Union of Angiology (IUA), recommend
use of low-molecular-weight heparins (LMWHs) for the treatment of acute VTE and prevention of
recurrence, and for prophylaxis in surgical and medical patients. This review highlights current
inadequacies in the provision of thromboprophylaxis, and considers the clinical implications of the
European guidelines on the prevention and treatment of VTE.
Introduction
The importance of preventing VTE
Venous thromboembolism (VTE), which includes deep
vein thrombosis (DVT) and pulmonary embolism (PE), is
an important cause of avoidable morbidity and mortality.
Generally, massive PE occurs without warning. For
patients dying in hospital as a result of PE, a diagnosis of
PE has not even been considered in 70–80% of cases prior
to death [1-4]. Although PE is a well-known complication
of surgery, the risk is often underestimated in non-surgical
patients, and approximately 75% of hospitalised patients
suffering a fatal PE are actually medical patients [5,6].
Patients surviving an initial VTE event are at increased risk
of recurrence [7], and are also at risk from considerable
morbidity due to chronic venous insufficiency and pul-
monary hypertension, which reduce quality of life and
increase healthcare costs [8-10].
There is a strong association between asymptomatic DVT
and the subsequent development of symptomatic VTE
[11]. However, routine screening of patients for asympto-
matic DVT is logistically problematic and is neither effec-
tive in preventing clinically significant VTE nor cost
effective [12,13]. Consequently, prophylaxis is the most
effective way of reducing morbidity and mortality among
susceptible patients. Current clinical guidelines provide
recommendations for thromboprophylaxis for many
groups of hospitalised patients [12,13]. However, despite
the widely accepted benefits, routine thromboprophylaxis
for at-risk patients remains underused [14-18]. An inter-
national consensus group, including the International
Union of Angiology (IUA), has recently issued detailed
guidelines for the prevention and treatment of VTE [13].
The recommendations for prophylaxis have been based
on a comprehensive review of published, peer-reviewed
reports of randomised comparisons of different methods
of thromboprophylaxis. They are fully consistent with
those recently delivered by the American College of Chest
Physicians [12].
This review aims to highlight the need for greater efforts in
preventing VTE and considers the clinical implications of
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the recent European guidelines on the prevention and
treatment of VTE.
Which patients should be considered for routine 
thromboprophylaxis?
Risk factors for VTE are well known (Table 1). Patients
with VTE generally have two or more risk factors, and the
effects of multiple risk factors on VTE risk are additive. The
type and duration of prophylaxis depends on whether the
risk factors are transient (e.g., trauma, surgery, infection,
the postpartum period) or persistent (e.g., advanced age,
obesity, history of VTE, thrombophilia). Patients admit-
ted to hospital are at particular risk of VTE, and the risk
remains elevated after discharge [19,20]. This is particu-
larly important in view of the current trend towards reduc-
ing the duration of inpatient stay, and suggests that
patients will increasingly be discharged while still at risk.
Furthermore, clinical events occurring after discharge
from hospital can give the false impression of a declining
risk of VTE related to hospitalisation.
The risks of VTE in surgical patients and the need for
appropriate thromboprophylaxis have long been recog-
nised. The risks are particularly high for orthopaedic sur-
gery, where routine use of thromboprophylaxis is
standard practice. Non-orthopaedic surgical patients are
classified as being at high, medium or low risk of develop-
ing VTE on the basis of known risk factors (see additional
file 1), and receive prophylaxis according to their level of
risk [13]. However, patients hospitalised for an acute
medical illness are also at increased risk for VTE. Hospital-
isation for an acute medical illness has been shown to be
independently associated with an approximately 8-fold
increased relative risk for VTE [21]. The European guide-
lines highlight the fact that acute medical conditions such
as stroke, congestive heart failure, respiratory disease,
infections or myocardial infarction are associated with a
high risk of VTE. The risk of VTE may be further increased
by reduced mobility, cancer, or patient-related factors
such as previous VTE, advancing age, obesity and coagula-
tion disorders [13]. These risk factors are similar to those
discussed in the recent guidelines on the prevention of
VTE issued by the American College of Chest Physicians
(ACCP) [12]. Both the European and ACCP guidelines
recommend assessment of all hospitalised medical
patients for risk of VTE so that appropriate thrombo-
prophylaxis can be provided [12,13].
Patients with cancer are at particular risk from VTE, and it
has been estimated that they have a 6-fold higher risk for
VTE than non-cancer patients [21]. It is notable that PE is
the second commonest cause of death in cancer patients,
the first cause being the cancer itself [22]. Malignancy is
associated with a hypercoagulable state, and several addi-
tional risk factors for VTE may co-exist in cancer patients
[23]. Thromboprophylaxis is recommended for surgical
cancer patients and for hospitalised cancer patients con-
fined to bed with an acute illness [13]. Although cancer
therapies have been associated with an increased risk of
VTE [24,25], there is currently insufficient evidence to rec-
ommend prophylaxis routinely in ambulant, non-surgical
cancer patients [13].
How should VTE be prevented in at-risk patients?
Prevention is preferable to treatment of VTE because early
symptoms and signs are unreliable predictors of clinically
significant thromboembolic events, and fatal PE can occur
without warning [12,13]. The approaches for prevention
and treatment of VTE recommended in the recent Euro-
pean guidelines are based on published evidence in each
clinical situation. The recommendations are graded (A-C)
based on the level of supporting clinical evidence (Table
2) [13].
Following a review of available evidence, the European
consensus group concluded that there was no major dif-
ference between low-dose unfractionated heparin
(LDUH) and low-molecular-weight heparins (LMWHs)
when used for prophylaxis in general surgical patients
[13]. LDUH or LMWH are recommended for general sur-
gical patients identified as being at moderate or high risk,
with prophylaxis commencing prior to the operation and
continuing postoperatively (Grade A). An alternative
approach for moderate-risk patients, particularly those in
whom the risk of bleeding may be high, involves mechan-
ical methods of prophylaxis (i.e., graduated elastic com-
pression stockings and intermittent pneumatic
compression) until the patient is ambulant (Grade A).
Mechanical methods may also be used in conjunction
with LDUH or LMWH in high-risk patients (Grade B). Use
of fondaparinux in high-risk patients is a Grade B recom-
mendation. In the absence of evidence from prospective
clinical trials, these recommendations may be extrapo-
lated to patients undergoing vascular or bariatric surgery
(Grade C).
The European guidelines recommend specific prophylac-
tic approaches for each type of orthopaedic surgery [13].
For example, for patients undergoing elective hip replace-
Table 1: Risk factors for venous thromboembolism [13]
• Immobility • Malignancy
• Trauma • History of VTE
• Surgery • Varicose veins
• Infection • Dehydration
• The postpartum period • Hormone therapy
• Advanced age • Cancer therapies
• Obesity • Thrombophilia
• Acute medical illness
VTE, venous thromboembolismThrombosis Journal 2008, 6:13 http://www.thrombosisjournal.com/content/6/1/13
Page 3 of 5
(page number not for citation purposes)
ment, the recommended approach involves LMWH, fon-
daparinux or oral anticoagulant therapy, in addition to
mechanical methods of prophylaxis (Grade A). Prophy-
laxis should be continued for 4–6 weeks with LMWH
(Grade A) or fondaparinux (Grade C). For patients under-
going elective knee joint replacement, recommendations
include LMWH or warfarin (Grade A), fondaparinux
(Grade B) and mechanical methods (Grade B). Patients
undergoing hip fracture surgery are at extremely high risk
for DVT and fatal PE, and LMWH, fondaparinux, oral anti-
coagulant therapy or LDUH are recommended (Grade A).
Throughout the guidelines, the IUA consensus group
emphasises that mechanical methods should be consid-
ered whenever pharmacological prophylaxis is contrain-
dicated.
What treatment approaches are recommended for VTE?
Patients with VTE receive anticoagulants to treat the acute
event and prevent fatal PE, and also to minimise the risks
of developing post-thrombotic syndrome and recurrent
VTE. For many years, unfractionated heparin (UFH) has
been the standard treatment for acute VTE. However, clin-
ical trial data show that LMWHs are more effective than
UFH for the initial treatment of VTE and are associated
with less major bleeding [26,27]. As a consequence,
LMWHs are replacing UFH in the treatment of acute VTE.
The recent European guidelines recommend that LMWH
should be used in the initial treatment of VTE, followed by
oral anticoagulant therapy for 3 months, or longer in the
case of idiopathic VTE (Grade A) [13]. These recommen-
dations are fully consistent with those recently delivered
by the American College of Chest Physicians [28].
On the basis of data from two clinical trials [29,30], fon-
daparinux may be used as an alternative to LMWH.
In patients with cancer, the IUA guidelines recommend
either LMWH or UFH for initial treatment of VTE (Grade
A), but note that outpatient therapy with LMWH is pre-
ferred, particularly in patients with a reduced life expect-
ancy in whom quality of life becomes a priority [13].
Recent studies have shown home treatment with LMWH
to be feasible in the majority of patients with cancer and
acute VTE [31,32]. For prevention of recurrent VTE in
patients with cancer, prophylaxis with the LMWH
dalteparin is recommended for 6 months using the dosing
regimen that was shown to be effective in a major clinical
trial (Grade B) [33]. This regimen involves intensive ini-
tial anticoagulation for 1 month (200 IU/kg once daily)
followed by less intensive anticoagulation for 5 months
(150 IU/kg once daily) to reduce the risk of bleeding. In
view of the ongoing risk of VTE in patients with cancer,
continued treatment should be considered for as long as
the cancer is active or while patients are receiving antican-
cer therapy (Grade C) [13].
Is there any difference between individual LMWHs?
LMWHs are manufactured by a variety of different meth-
ods, and each LMWH has a unique chemical structure that
confers specific pharmacokinetic and pharmacodynamic
properties. Regulatory bodies in Europe and North Amer-
ica regard LMWHs as distinct chemical entities, and advise
that they should not be used interchangeably [13,34].
Very little is known about the relative efficacy and safety
of different LMWHs in the treatment and prevention of
VTE. The few direct comparative trials of LMWHs that
have been conducted in the treatment of acute VTE [35]
and thromboprophylaxis [36-39] have not revealed any
notable differences in clinical efficacy or safety between
individual LMWHs.
In the absence of sufficient comparative data, each LMWH
should be dosed according to the labelling and recom-
mendations issued by the manufacturer. Thus, the clinical
results from one LMWH should not be extrapolated to
another. Adopting an evidence-based approach to patient
management is essential in the use of LMWHs, and only
doses of drugs that have been adequately evaluated in
well-designed clinical trials should be considered for use
in a particular indication.
Conclusion: improving compliance with clinical 
guidelines
Despite the existence of comprehensive consensus guide-
lines for the prevention and treatment of VTE [7,12,13],
thromboprophylaxis remains underused [14-18]. Reasons
for underuse are complex and include underestimation of
the risks of VTE, underestimation of the impact of non-
Table 2: Grades of recommendation in the IUA guidelines [13]
Grade Clinical evidence
A • Level 1 evidence from randomised controlled trials with consistent results, which are directly applicable to the target population.
B • Level 1 evidence from a single high-quality randomised controlled trial, which is directly applicable to the target population.
• Level 1 evidence from randomised controlled trials with less consistent results, limited power or other methodological problems, which 
are directly applicable to the target population.
• Level 1 evidence from randomised controlled trials extrapolated from a different group of patients to the target population.
C • Level 2 evidence from well-conducted observational studies with consistent results, which are directly applicable to the target population.
IUA, International Union of AngiologyThrombosis Journal 2008, 6:13 http://www.thrombosisjournal.com/content/6/1/13
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fatal outcomes of VTE, lack of awareness of relevant guide-
lines, absence of local thromboprophylaxis strategies, and
concerns about the risk of bleeding. Concerns about the
risk of bleeding are generally unfounded, as the risk of
bleeding complications with LMWHs is low [12,13].
Nonetheless, this is often cited as a reason for underuse of
thromboprophylaxis, particularly in surgical patients
[12,16,39].
Improving compliance with thromboprophylaxis guide-
lines is a complex task that needs to include improved
thrombotic risk-assessment methods, familiarisation of
clinicians with current best practice, and facilitation of
appropriate prescribing of prophylaxis [39]. Several sim-
ple and clinically relevant risk assessment models are now
available to assist with VTE risk stratification of hospital-
ised patients [6,40,41]. Recent risk assessment models in
medical and surgical patients have also included sug-
gested thromboprophylaxis strategies [6,41]. Evidence
suggests that the prevention of VTE can be improved by
use of computerised reminders for clinicians to consider
prophylaxis in at-risk patients [42,43]. Although these ini-
tiatives go some way towards improving the prescribing of
thromboprophylaxis, additional efforts are still needed to
increase the routine use of thromboprophylaxis in
patients at risk of VTE to further reduce the morbidity and
mortality of this preventable condition.
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